Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $75.1 million.

  • Viking Therapeutics' Cash from Financing Activities rose 741030.0% to $75.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.4 million, marking a year-over-year decrease of 8751.94%. This contributed to the annual value of $76.4 million for FY2025, which is 8751.94% down from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Cash from Financing Activities is $75.1 million, which was up 741030.0% from $480000.0 recorded in Q3 2025.
  • Viking Therapeutics' Cash from Financing Activities' 5-year high stood at $606.0 million during Q1 2024, with a 5-year trough of -$5.0 million in Q1 2022.
  • In the last 5 years, Viking Therapeutics' Cash from Financing Activities had a median value of $753500.0 in 2024 and averaged $48.6 million.
  • Per our database at Business Quant, Viking Therapeutics' Cash from Financing Activities skyrocketed by 2277021.28% in 2022 and then plummeted by 84000.0% in 2023.
  • Viking Therapeutics' Cash from Financing Activities (Quarter) stood at $47000.0 in 2021, then soared by 22770.21% to $10.7 million in 2022, then plummeted by 98.25% to $188000.0 in 2023, then surged by 431.91% to $1.0 million in 2024, then skyrocketed by 7410.3% to $75.1 million in 2025.
  • Its Cash from Financing Activities stands at $75.1 million for Q4 2025, versus $480000.0 for Q3 2025 and $507000.0 for Q2 2025.